Reversible ageusia associated with romidepsin therapy

American Journal of Health-System Pharmacy

Volumn 70, Issue 17, 2013, Pages 1502-1505

  Cooper, Maryann R ^a   Brewer, Sara ^b   Broketa, Goran ^c  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Hallmark Health System   (United States)

^c Manchester VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BEXAROTENE; BUSPIRONE; CALCIUM CARBONATE; COLECALCIFEROL; CYANOCOBALAMIN; DENILEUKIN DIFTITOX; ETIRACETAM; FENOFIBRATE; GABAPENTIN; HYDROCODONE; LISINOPRIL; MACROGOL; MORPHINE; MULTIVITAMIN; NORTRIPTYLINE; ONDANSETRON; PARACETAMOL; ROMIDEPSIN; SIMVASTATIN; SULFADIAZINE SILVER; VORINOSTAT; ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE;

AGED; AGEUSIA; ARTICLE; CANCER PATIENT; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; MALE; METALLIC TASTE; MULTIPLE CYCLE TREATMENT; QUALITY OF LIFE; SCORING SYSTEM; SEZARY SYNDROME; SKIN BIOPSY; SKIN MANIFESTATION; SYMPTOM; TASTE; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; CHEMICALLY INDUCED; LYMPHOMA, T-CELL, CUTANEOUS; TREATMENT OUTCOME;

AGED; AGEUSIA; ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; TREATMENT OUTCOME;

EID: 84899036866     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/130024     Document Type: Article

References (20)

1. Naik BS, Shetty N, Maben EV. Drug-induced taste disorders. Eur J Intern Med. 2010; 21:240-3.
2. Hovan AJ, Williams PM, Stevenson-Moore P et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer. 2010; 18:1081-7.
3. Hong JH, Omur-Ozbek P, Stanek BT et al. Taste and odor abnormalities in cancer patients. J Support Oncol. 2009; 7:58-65.
4. Zabernigg A, Gamper EM, Giesinger JM et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist. 2010; 15:913-20.
5. Lindley C, McCune JS, Thomason TE et al. Perception of chemotherapy side effects in cancer versus noncancer patients. Cancer Pract. 1999; 7:59-65.
6. Doty RL, Shah M, Bromley SM. Drug-induced taste disorders. Drug Saf. 2008; 31:199-215.
7. Comeau TB, Epstein JB, Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer. 2001; 9:575-80.
8. Berteretche MV, Dalix AM, d'Ornano AM et al. Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer. 2004; 12:571-6.
9. Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer. 2008; 16:275-83.
10. Steinbach S, Hummel T, Bohner C et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol. 2009; 27:1899-905.
11. Gamper EM, Zabernigg A, Winter LM et al. Coming to your senses: detecting taste and smell alterations in chemotherapy patients, a systematic review. J Pain Symptom Manage. 2012; 44:880-95.
12. Wickman RS, Rehwaldt M, Kefer C et al. Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum. 1999; 16:697-706.
13. DeWys WD. Changes in taste sensation and feeding behaviour in cancer patients: a review. J Hum Nutr. 1978; 32:447-53.
14. Bernhardson BM, Tishelman C, Rutqvist LE. Taste and smell changes in patients receiving chemotherapy: distress, impact on quality of life, and self-care strategies. Cancer Nurs. 2009; 32:45-54.
15. Kiewe P, Jovanovic S, Thiel E et al. Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin. Ann Pharmacother. 2004; 38:1212-4.
16. National Insitutes of Health. Common terminology criteria for adverse events: version 4.03 (June 14, 2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf (accessed 2013 Apr 18).
17. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27:5410-7.
18. Piekarz RL, Frye R, Prince HM et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011; 117:5827-34.
19. Istodax (romidepsin) package insert. Summit, NJ: Celgene Corporation; 2009.
20. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.